Skip to main content

Table 1 Clinical characteristics of patients (means ± SEM)

From: Perindopril treatment promote left ventricle remodeling in patients with heart failure screened positive for autoantibodies against angiotensin II type 1 receptor

Index (+) anti-AT1-AR (−) anti-AT1-AR P-value
(n = 82) (n = 56)
Demographic    
Age (years) 66.6 ± 1.2 65.1 ± 1.6 ns
Sex (male) 42 (51.2%) 30 (53.6%) ns
BMI (kg/m2) 24.3 ± 0.9 24.3 ± 0.6 ns
Disease history (years) 6.1 ± 0.3 8.7 ± 0.4 <0.01
Aetiology    
CAD cases (%) 24 (29.3%) 26 (46.4%) ns
DCM cases (%) 26 (31.7%) 8 (14.3%) ns
HHD cases (%) 32 (39.0%) 22 (39.3%) ns
Physiological characteristics    
Heart rate (bpm) 94.2 ± 1.2 93.8 ± 1.2 ns
SBP (mmHg) 129.9 ± 1.8 125.0 ± 1.8 ns
DBP (mmHg) 78.2 ± 0.9 75.5 ± 1.1 ns
LVEDD (mm) 69.5 ± 0.6 69.9 ± 0.9 ns
LVESD (mm) 56.2 ± 0.6 55.7 ± 0.8 ns
LVEF (%) 34.1 ± 0.6 33.8 ± 0.9 ns
6 min walk test (m) 303.8 ± 3.7 301.8 ± 4.3 ns
  1. CAD: coronary artery disease; DCM: dilated cardiomyopathy; HHD: hypertensive heart disease; SBP: systolic blood pressure; DBP: diastolic blood pressure; LVEDD: left ventricular end-diastolic dimension; LVESD: left ventricular end-systolic dimension; LVEF: left ventricular ejection fraction.